Correspondence 0001493152-23-024550 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: July 14, 2023 · CIK: 0001859007 · Accession: 0001493152-23-024550

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-272657

Date

July 14, 2023

Author

ZYVERSA

Form

CORRESP

Company

ZyVersa Therapeutics, Inc.

Letter

July 14, 2023

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F Street, N.E.

Washington, D.C. 20549

Attn: Joshua Gorsky

Re: ZyVersa Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-272657

Ladies and Gentlemen:

ZyVersa Therapeutics, Inc. hereby requests that its acceleration request dated July 11, 2023, be withdrawn. Please call Jack Hogoboom of Lowenstein Sandler LLP at (973) 587-2382 with any questions.

Sincerely,
ZYVERSA
THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

July
14, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

Office
of Life Sciences

100
F Street, N.E.

Washington,
D.C. 20549

    Attn:
    Joshua
    Gorsky

    Re:
    ZyVersa
    Therapeutics, Inc.

Registration
Statement on Form S-1, as amended

File
No. 333-272657

Ladies
and Gentlemen:

ZyVersa
Therapeutics, Inc. hereby requests that its acceleration request dated July 11, 2023, be withdrawn. Please call Jack Hogoboom of Lowenstein
Sandler LLP at (973) 587-2382 with any questions.

    Sincerely,

    ZYVERSA
    THERAPEUTICS INC.

    By:
    /s/
    Stephen Glover

    Name:
    Stephen
    Glover

    Title:
    Chief
    Executive Officer

SecProbe.io